,pmid,doi,author,publicationyear,population,studyaim,studydesign,studysetting,totalsamplesize,sex,primaryoutcome,secondaryoutcomes,note,meanweight,meanwt_sd,lowerboundweight,upperboundweight,rangeweight,meanBMI,meanBMI_sd,lowerboundBMI,upperboundBMI,rangeBMI,meanDBP,meanDBP_sd,lowerboundDBP,upperboundDBP,meanSBP,meanSBP_sd,lowerboundSBP,upperboundSBP,meanAGE,meanAGE_sd,noofFEMALES,noofMALES,changeinbabaseBMI,changeinbabaseDBP,changeinbabaseSBP,extracted_portion,intervention_control,pmid_author_intervention,Males;Females,Sample(n),"Age (mean,sd)","Weight (mean,sd)","BMI (mean,sd)","SBP (mean,sd)","DBP (mean,sd)"
0,21893621,10.7326/0003-4819-155-5-201109060-00005, Torgeir T. Søvik,2011,Mixed,To determine whether duodenal switch leads to greater weight loss and more favorable improvements in cardiovascular risk factors and quality of life than gastric bypass.,Randomised controlled trial,Norway_Sweden,60.0,Both,Change in BMI after 2 years,"anthropometric measures; concentrations of blood lipids, glucose, insulin, C-reactive protein, and vitamins; and health-related quality of life and adverse events",Patients with a body mass index between 50 and 60 kg/m2 were randomly assigned to undergo gastric bypass or duodenal switch; aged 20 to 50 years.,162.0,24.1,0.0,0.0,,54.8,3.24,48.4496,61.1504,,82.6,11.8,59.471999999999994,105.728,134.0,20.0,94.8,173.2,35.2,7.0,23.0,8.0,0.0,0.0,0.0,GB,intervention,21893621_ Torgeir T. Søvik_GB,8.0;23.0,31.0,35.2(7.0),162.0(24.1),54.8(3.24),134.0(20.0),82.6(11.8)
1,21893621,10.7326/0003-4819-155-5-201109060-00005, Torgeir T. Søvik,2011,Mixed,To determine whether duodenal switch leads to greater weight loss and more favorable improvements in cardiovascular risk factors and quality of life than gastric bypass.,Randomised controlled trial,Norway_Sweden,60.0,Both,Change in BMI after 2 years,"anthropometric measures; concentrations of blood lipids, glucose, insulin, C-reactive protein, and vitamins; and health-related quality of life and adverse events",Patients with a body mass index between 50 and 60 kg/m2 were randomly assigned to undergo gastric bypass or duodenal switch; aged 20 to 50 years.,162.0,19.7,0.0,0.0,,55.2,3.49,48.3596,62.040400000000005,,88.3,12.9,63.016,113.584,140.0,18.7,103.348,176.652,36.1,5.26,19.0,10.0,0.0,0.0,0.0,DS,control,21893621_ Torgeir T. Søvik_DS,10.0;19.0,29.0,36.1(5.26),162.0(19.7),55.2(3.49),140.0(18.7),88.3(12.9)
2,20587720, 10.2337/dc09-1833,Miguel F Herrera,2010,EUR,"To assess the additional effect of sudden visceral fat reduction by omentec- tomy on metabolic syndrome, acute-phase reactants, and inflammatory mediators in patients with grade III obesity (G-III O) undergoing laparoscopic Roux-en-Y gastric bypass (LRYGB)",A randomised trial,Mexico,24.0,Both,"Components of metabolic syndrome: BMI, SBP, DBP,Glucose, Insulin, Total cholesterol, triglycerides and lipoproteins","Inflammatory mediators(IL6, CRP, leptin, adiponectin)","Patients with metabolic syndrome with grade III obesity some with diabetes, dyslipidemia and hypertension.",0.0,0.0,0.0,0.0,,44.9,3.1,38.824,50.976,,85.5,7.9,70.016,100.984,131.8,9.8,112.59200000000001,151.008,36.8,12.9,8.0,3.0,0.0,0.0,0.0,LRYGB_Omentectomy,control,20587720_Miguel F Herrera_LRYGB_Omentectomy,3.0;8.0,11.0,36.8(12.9),0.0(0.0),44.9(3.1),131.8(9.8),85.5(7.9)
3,20587720, 10.2337/dc09-1833,Miguel F Herrera,2010,EUR,"To assess the additional effect of sudden visceral fat reduction by omentec- tomy on metabolic syndrome, acute-phase reactants, and inflammatory mediators in patients with grade III obesity (G-III O) undergoing laparoscopic Roux-en-Y gastric bypass (LRYGB)",A randomised trial,Mexico,24.0,Both,"Components of metabolic syndrome: BMI, SBP, DBP,Glucose, Insulin, Total cholesterol, triglycerides and lipoproteins","Inflammatory mediators(IL6, CRP, leptin, adiponectin)","Patients with metabolic syndrome with grade III obesity some with diabetes, dyslipidemia and hypertension.",0.0,0.0,0.0,0.0,,44.5,4.3,36.072,52.928,,89.0,3.9,81.356,96.644,134.6,6.9,121.076,148.124,39.8,11.1,10.0,1.0,0.0,0.0,0.0,LRYGB,intervention,20587720_Miguel F Herrera_LRYGB,1.0;10.0,11.0,39.8(11.1),0.0(0.0),44.5(4.3),134.6(6.9),89.0(3.9)
4,33963974,10.1007/s11695-021-05454-2,Oral Ospanov,2021,East Asian,To compare the treatment modalities in terms of changes in BMI and telomere length (as a possible biomarker of life expectan cy) and resolution of MetS components.,RCT,Kazakhstan,60.0,Both,Change in BMI,"Change in leukocyte telomere length and other MetS components including insulin resistance, dyslipidemia and hypertension","Patients with BMI ranging between 35 and 50, with MetS characterised by hypertension, prediabetic with obesity and T2D ",101.13,26.09,0.0,0.0,,36.51,0.0,0.0,0.0,,92.95,3.24,86.59960000000001,99.3004,138.9,14.03,111.4012,166.3988,47.25,9.85,13.0,7.0,8.1,0.0,0.0,HDER,control,33963974_Oral Ospanov_HDER,7.0;13.0,20.0,47.25(9.85),101.13(26.09),36.51(0.0),138.9(14.03),92.95(3.24)
5,33963974,10.1007/s11695-021-05454-2,Oral Ospanov,2021,East Asian,To compare the treatment modalities in terms of changes in BMI and telomere length (as a possible biomarker of life expectan cy) and resolution of MetS components.,RCT,Kazakhstan,60.0,Both,Change in BMI,"Change in leukocyte telomere length and other MetS components including insulin resistance, dyslipidemia and hypertension","Patients with BMI ranging between 35 and 50, with MetS characterised by hypertension, prediabetic with obesity and T2D ",108.95,15.69,0.0,0.0,,39.88,0.0,0.0,0.0,,92.25,3.97,84.4688,100.0312,135.8,6.93,122.21720000000002,149.3828,38.6,6.89,18.0,2.0,5.8,0.0,0.0,LOAGB-OSPAN,intervention,33963974_Oral Ospanov_LOAGB-OSPAN,2.0;18.0,20.0,38.6(6.89),108.95(15.69),39.88(0.0),135.8(6.93),92.25(3.97)
6,33963974,10.1007/s11695-021-05454-2,Oral Ospanov,2021,East Asian,To compare the treatment modalities in terms of changes in BMI and telomere length (as a possible biomarker of life expectan cy) and resolution of MetS components.,RCT,Kazakhstan,60.0,Both,Change in BMI,"Change in leukocyte telomere length and other MetS components including insulin resistance, dyslipidemia and hypertension","Patients with BMI ranging between 35 and 50, with MetS characterised by hypertension, prediabetic with obesity and T2D ",128.95,23.71,0.0,0.0,,45.91,0.0,0.0,0.0,,93.9,4.15,85.766,102.034,142.4,25.11,93.18440000000001,191.6156,48.7,8.54,15.0,5.0,5.5,0.0,0.0,LMGB-OAGB,intervention,33963974_Oral Ospanov_LMGB-OAGB,5.0;15.0,20.0,48.7(8.54),128.95(23.71),45.91(0.0),142.4(25.11),93.9(4.15)
7,32805133,10.7326/M19-3781,Carlos A Schiavon,2020,EUR,To determine the 3-year effects of Roux-en-Y gastric bypass (RYGB) on blood pressure (BP) compared with medical therapy (MT) alone,Randomised controlled trial,Brazil,100.0,Both,30% reduction in total number of antihypertensive medications while maintaining BP less than 140/90 mm Hg,"Number of antihypertensive medications, hypertension remission, and BP control according to current guidelines (<130/80 mm Hg)",Participants with hypertension receiving at least 2 medications and BMI ranging between 30 and 39.9 kg/m2 aged 18 to 65 years.,100.1,0.0,96.3,103.9,,36.4,2.9,35.5,37.4,,77.3,0.0,74.5,80.2,122.8,0.0,118.5,127.0,44.6,9.2,35.0,15.0,0.0,0.0,0.0,MT,control,32805133_Carlos A Schiavon_MT,15.0;35.0,50.0,44.6(9.2),100.1(0.0),36.4(2.9),122.8(0.0),77.3(0.0)
8,32805133,10.7326/M19-3781,Carlos A Schiavon,2020,EUR,To determine the 3-year effects of Roux-en-Y gastric bypass (RYGB) on blood pressure (BP) compared with medical therapy (MT) alone,Randomised controlled trial,Brazil,100.0,Both,30% reduction in total number of antihypertensive medications while maintaining BP less than 140/90 mm Hg,"Number of antihypertensive medications, hypertension remission, and BP control according to current guidelines (<130/80 mm Hg)",Participants with hypertension receiving at least 2 medications and BMI ranging between 30 and 39.9 kg/m2 aged 18 to 65 years.,102.0,0.0,98.1,105.8,,37.4,2.4,32.696,42.104,,77.6,0.0,74.7,80.5,123.0,0.0,118.7,127.2,43.1,9.2,41.0,9.0,0.0,0.0,0.0,RYGBplusMT,intervention,32805133_Carlos A Schiavon_RYGBplusMT,9.0;41.0,50.0,43.1(9.2),102.0(0.0),37.4(2.4),123.0(0.0),77.6(0.0)
9,34981324,10.1007/s11695-021-05868-y,Moheb S Eskandaros ,2022,AFR,"The aim of this study was to perform a comparison of the operative and postoperative outcomes regarding BMI, asso ciated medical conditions, and nutritional status between the standard RYGB (BPL: 50 cm and AL: 150 cm) and long RYGB (BPL: 100 cm and AL: 100 cm) for up to 3 years postoperatively.",Randomised prospective trial,Egypt,150.0,Both,"BMI, % of total weight loss (%TWL)","effect on diabetes (DM), hypertension (HTN), dyslipidemia, and nutritional statuses","Participants with BMI between 40-50 kg/m2 and with hypertension, diabetes and dyslipidemia",126.26,8.213,0.0,0.0,,45.3749,2.9261,39.63974399999999,51.110056,,95.74,8.963,78.17251999999999,113.30748,136.84,7.97,121.2188,152.4612,47.04,7.411,37.0,20.0,0.0,0.0,0.0,L-RYGB,control,34981324_Moheb S Eskandaros _L-RYGB,20.0;37.0,57.0,47.04(7.411),126.26(8.213),45.3749(2.9261),136.84(7.97),95.74(8.963)
10,34981324,10.1007/s11695-021-05868-y,Moheb S Eskandaros ,2022,AFR,"The aim of this study was to perform a comparison of the operative and postoperative outcomes regarding BMI, asso ciated medical conditions, and nutritional status between the standard RYGB (BPL: 50 cm and AL: 150 cm) and long RYGB (BPL: 100 cm and AL: 100 cm) for up to 3 years postoperatively.",Randomised prospective trial,Egypt,150.0,Both,"BMI, % of total weight loss (%TWL)","effect on diabetes (DM), hypertension (HTN), dyslipidemia, and nutritional statuses","Participants with BMI between 40-50 kg/m2 and with hypertension, diabetes and dyslipidemia",127.33,7.488,0.0,0.0,,46.25,2.515,41.3206,51.1794,,93.47,7.92,77.9468,108.9932,139.28,10.091,119.50164000000001,159.05836,46.72,8.352,42.0,22.0,0.0,0.0,0.0,S-RYGB,intervention,34981324_Moheb S Eskandaros _S-RYGB,22.0;42.0,64.0,46.72(8.352),127.33(7.488),46.25(2.515),139.28(10.091),93.47(7.92)
11,29133606,10.1161/CIRCULATIONAHA.117.032130,Carlos Aurelio Schiavon ,2018,Mixed,To assess the impact of bariatric surgery on hypertension improvement in patients with obesity.,RCT,Brazil,100.0,Both,"primary end point was reduction of ≥30% of the total number of antihypertensive medications while maintaining systolic and diastolic blood pressure <140 mm Hg and 90 mm Hg, respectively, at 12 months.","Secondary end points included number of antihypertensive drugs, systolic and blood pressure (offic and 24-hour ABPM), weight and BMI, waist circumference, fasting plasma glucose and glycohemoglobin, homeostasis model assessment of insulin resistance index, lipid profil (low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides levels), uric acid, high-sensitivity C-reactive protein levels, interventricular septum diastolic thickness, a 10-year Framingham risk score, and adverse events. secondary end points defined post hoc: remission of hypertension (defined as systolic and diastolic blood pressure <140 mm Hg and 90 mm Hg, respectively, with out medications based on office blood pressure), remission of hypertension (defined as systolic and diastolic blood pressure <140 mm Hg and 90 mm Hg, respectively, without medica tions based on 24-hour ABPM), and reduction of ≥30% of the total number of antihypertensive medications while maintain ing an office systolic blood pressure <120 mm Hg (SPRINT lev els [Systolic Blood Pressure Intervention Trial]) at 12 months.",Patients btw 18-65 years with hypertension; BMI between 30-39.9 and taking at least 2 antihypertensive medication,102.0,13.6,0.0,0.0,,37.4,2.4,32.696,42.104,,77.6,7.0,63.879999999999995,91.32,123.0,11.6,100.264,145.736,43.1,9.2,41.0,9.0,0.0,0.0,0.0,RYGBplusMT,intervention,29133606_Carlos Aurelio Schiavon _RYGBplusMT,9.0;41.0,50.0,43.1(9.2),102.0(13.6),37.4(2.4),123.0(11.6),77.6(7.0)
12,29133606,10.1161/CIRCULATIONAHA.117.032130,Carlos Aurelio Schiavon ,2018,Mixed,To assess the impact of bariatric surgery on hypertension improvement in patients with obesity.,RCT,Brazil,100.0,Both,"primary end point was reduction of ≥30% of the total number of antihypertensive medications while maintaining systolic and diastolic blood pressure <140 mm Hg and 90 mm Hg, respectively, at 12 months.","Secondary end points included number of antihypertensive drugs, systolic and blood pressure (offic and 24-hour ABPM), weight and BMI, waist circumference, fasting plasma glucose and glycohemoglobin, homeostasis model assessment of insulin resistance index, lipid profil (low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides levels), uric acid, high-sensitivity C-reactive protein levels, interventricular septum diastolic thickness, a 10-year Framingham risk score, and adverse events. secondary end points defined post hoc: remission of hypertension (defined as systolic and diastolic blood pressure <140 mm Hg and 90 mm Hg, respectively, with out medications based on office blood pressure), remission of hypertension (defined as systolic and diastolic blood pressure <140 mm Hg and 90 mm Hg, respectively, without medica tions based on 24-hour ABPM), and reduction of ≥30% of the total number of antihypertensive medications while maintain ing an office systolic blood pressure <120 mm Hg (SPRINT lev els [Systolic Blood Pressure Intervention Trial]) at 12 months.",Patients btw 18-65 years with hypertension; BMI between 30-39.9 and taking at least 2 antihypertensive medication,100.1,14.0,0.0,0.0,,36.4,2.9,30.715999999999998,42.083999999999996,,78.0,9.3,59.772,96.22800000000001,122.8,12.9,97.51599999999999,148.084,44.6,9.2,35.0,15.0,0.0,0.0,0.0,MT,control,29133606_Carlos Aurelio Schiavon _MT,15.0;35.0,50.0,44.6(9.2),100.1(14.0),36.4(2.9),122.8(12.9),78.0(9.3)
13,32540150,10.1016/j.soard.2020.04.033,Ville Wallenius ,2020,EUR,"To compare diabetes remission rates (glycosylated hemoglobin  6.0%, without diabetes medications) in obese T2D patients (body mass index, 35–50) undergoing RYGB or SG.",Randomised controlled trial,Sweden,49.0,Both,Remission of T2D within 1 year,"30-day surgical complication rates, weight loss, measured as reduc tion in BMI units, total weight loss (in kilograms), and per centage excess weight loss, as well as percentage weight loss, resolution of other co-morbidities associated with obesity and T2D.",Obese T2D patients with BMI of 35-50 kg/m2,119.0,15.4,0.0,0.0,,39.5,3.7,32.248,46.752,,86.8,8.4,70.336,103.264,137.9,15.9,106.736,169.06400000000002,49.1,9.2,12.0,13.0,0.0,0.0,0.0,RYGB,intervention,32540150_Ville Wallenius _RYGB,13.0;12.0,25.0,49.1(9.2),119.0(15.4),39.5(3.7),137.9(15.9),86.8(8.4)
14,32540150,10.1016/j.soard.2020.04.033,Ville Wallenius ,2020,EUR,"To compare diabetes remission rates (glycosylated hemoglobin  6.0%, without diabetes medications) in obese T2D patients (body mass index, 35–50) undergoing RYGB or SG.",Randomised controlled trial,Sweden,49.0,Both,Remission of T2D within 1 year,"30-day surgical complication rates, weight loss, measured as reduc tion in BMI units, total weight loss (in kilograms), and per centage excess weight loss, as well as percentage weight loss, resolution of other co-morbidities associated with obesity and T2D.",Obese T2D patients with BMI of 35-50 kg/m2,120.0,19.2,0.0,0.0,,40.8,4.1,32.763999999999996,48.836,,83.2,12.5,58.7,107.7,131.3,16.1,99.74400000000001,162.85600000000002,47.0,10.7,11.0,13.0,0.0,0.0,0.0,SG,control,32540150_Ville Wallenius _SG,13.0;11.0,24.0,47.0(10.7),120.0(19.2),40.8(4.1),131.3(16.1),83.2(12.5)
15,25919069, 10.1089/met.2014.0152,Fernando de Barros ,2015,Mixed,"To compare the early changes in endocrine–metabolic parameters associated with SG and GB, particularly with regard to the early remission of co-morbidities before significant weight loss",RCT,Brazil,51.0,Both,glycemic control 90 days after surgery,"secondary end points were the EWL90, a fall in HbA1c, systolic blood pressure (SBP), diastolic blood pressure ,14 15 (DBP), and lipid profile, and changes in hemoglobin, iron, ferritin, vitamin B12, folic acid, albumin, and uric acid.",Grade III morbidly obese participants older than 18 but less than 65 years.,123.22,19.78,0.0,0.0,98.9-177,45.62,6.51,32.8604,58.379599999999996,40-67.4,90.0,11.37,67.7148,112.2852,139.2,14.84,110.11359999999999,168.2864,38.24,9.51,23.0,2.0,0.0,0.0,0.0,SG,control,25919069_Fernando de Barros _SG,2.0;23.0,25.0,38.24(9.51),123.22(19.78),45.62(6.51),139.2(14.84),90.0(11.37)
16,25919069, 10.1089/met.2014.0152,Fernando de Barros ,2015,Mixed,"To compare the early changes in endocrine–metabolic parameters associated with SG and GB, particularly with regard to the early remission of co-morbidities before significant weight loss",RCT,Brazil,51.0,Both,glycemic control 90 days after surgery,"secondary end points were the EWL90, a fall in HbA1c, systolic blood pressure (SBP), diastolic blood pressure ,14 15 (DBP), and lipid profile, and changes in hemoglobin, iron, ferritin, vitamin B12, folic acid, albumin, and uric acid.",Grade III morbidly obese participants older than 18 but less than 65 years.,128.27,21.45,0.0,0.0,93.6-177.0,49.24,7.99,33.5796,64.9004,40.4-69.6,86.8,5.93,75.1772,98.4228,134.2,8.12,118.28479999999999,150.1152,35.2,10.83,23.0,2.0,0.0,0.0,0.0,GB,intervention,25919069_Fernando de Barros _GB,2.0;23.0,25.0,35.2(10.83),128.27(21.45),49.24(7.99),134.2(8.12),86.8(5.93)
17,34554379,10.1007/s11695-021-05702-5,Alan Robson,2021,EUR,"The study aimed to verify the systemic inflammatory response through the analysis of IGF-1, IL-23, and resistin levels and the lipid profile in severely obese women undergoing surgery for obesity and weight-related diseases.",RCT,Brazil,75.0,Female,"Systemic inflam matory profile 6 months after BS, as characterized by the blood levels of the inflammatory markers IGF-1, IL-23, and resistin",Any changes in clinical and anthropometric variables,Women with severe class III obesity with BMI above 40 and above 35 with comorbidities. the control constituted of those who did not meet the inclusion criteria and had no urgent need for surgery.,112.64,17.12,0.0,0.0,,46.35,5.46,35.6484,57.0516,,86.96,7.15,72.946,100.97399999999999,126.2,7.42,111.6568,140.7432,42.09,12.69,11.0,0.0,0.0,0.0,0.0,CG,control,34554379_Alan Robson_CG,0.0;11.0,11.0,42.09(12.69),112.64(17.12),46.35(5.46),126.2(7.42),86.96(7.15)
18,34554379,10.1007/s11695-021-05702-5,Alan Robson,2021,EUR,"The study aimed to verify the systemic inflammatory response through the analysis of IGF-1, IL-23, and resistin levels and the lipid profile in severely obese women undergoing surgery for obesity and weight-related diseases.",RCT,Brazil,75.0,Female,"Systemic inflam matory profile 6 months after BS, as characterized by the blood levels of the inflammatory markers IGF-1, IL-23, and resistin",Any changes in clinical and anthropometric variables,Women with severe class III obesity with BMI above 40 and above 35 with comorbidities. the control constituted of those who did not meet the inclusion criteria and had no urgent need for surgery.,125.48,20.35,0.0,0.0,,47.25,6.22,35.058800000000005,59.441199999999995,,87.6,15.55,57.12199999999999,118.078,129.58,17.74,94.80960000000002,164.3504,42.46,9.8,50.0,0.0,0.0,0.0,0.0,RYGB,intervention,34554379_Alan Robson_RYGB,0.0;50.0,50.0,42.46(9.8),125.48(20.35),47.25(6.22),129.58(17.74),87.6(15.55)
19,23163735,10.1111/cen.12109,Juan Jesús Tur,2013,EUR,"To examine the effects of a nonsurgical approach, Intensive Life style Intervention (ILI) on the therapy of morbid obesity",Randomised controlled trial,Spain,143.0,Both,Change in body weight and body mass index,"Percentage change fast- ing plasma Glucose (FPG), glycosylated haemoglobin (HbA1c) levels, blood pressure (BP) and levels of fasting lipids obtained at baseline and every 3 months after initiation of the interven- tion.",Morbidly obese participants,122.24,20.05,0.0,0.0,,45.79,4.97,36.0488,55.5312,,86.83,9.98,67.2692,106.3908,131.85,18.74,95.11959999999999,168.5804,47.84,11.52,43.0,17.0,0.0,0.0,0.0,ILI,control,23163735_Juan Jesús Tur_ILI,17.0;43.0,60.0,47.84(11.52),122.24(20.05),45.79(4.97),131.85(18.74),86.83(9.98)
20,23163735,10.1111/cen.12109,Juan Jesús Tur,2013,EUR,"To examine the effects of a nonsurgical approach, Intensive Life style Intervention (ILI) on the therapy of morbid obesity",Randomised controlled trial,Spain,143.0,Both,Change in body weight and body mass index,"Percentage change fast- ing plasma Glucose (FPG), glycosylated haemoglobin (HbA1c) levels, blood pressure (BP) and levels of fasting lipids obtained at baseline and every 3 months after initiation of the interven- tion.",Morbidly obese participants,132.81,24.37,0.0,0.0,,49.23,5.85,37.763999999999996,60.696,,82.84,8.88,65.43520000000001,100.2448,132.57,14.43,104.2872,160.8528,44.12,9.84,26.0,11.0,0.0,0.0,0.0,SOG,intervention,23163735_Juan Jesús Tur_SOG,11.0;26.0,37.0,44.12(9.84),132.81(24.37),49.23(5.85),132.57(14.43),82.84(8.88)
21,23163735,10.1111/cen.12109,Juan Jesús Tur,2013,EUR,"To examine the effects of a nonsurgical approach, Intensive Life style Intervention (ILI) on the therapy of morbid obesity",Randomised controlled trial,Spain,143.0,Both,Change in body weight and body mass index,"Percentage change fast- ing plasma Glucose (FPG), glycosylated haemoglobin (HbA1c) levels, blood pressure (BP) and levels of fasting lipids obtained at baseline and every 3 months after initiation of the interven- tion.",Morbidly obese participants,126.02,17.9,0.0,0.0,,46.76,4.62,37.7048,55.8152,,86.61,9.99,67.0296,106.1904,136.07,13.97,108.68879999999999,163.4512,46.86,10.26,29.0,17.0,0.0,0.0,0.0,COT,control,23163735_Juan Jesús Tur_COT,17.0;29.0,46.0,46.86(10.26),126.02(17.9),46.76(4.62),136.07(13.97),86.61(9.99)
22,194696,doi.org/10.1155/2015/194696,Bartolomé Burguera,2015,EUR,"Aimed at comparing the efficacy of two nonsurgical approaches versus bariatric surgery, on body weight changes and metabolic parameters in morbidly obese patients.",Randomised controlled trial,Spain,143.0,Both,Body weight in KGs and Body mass index in kg/m2.,"Percent changes in fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), and blood pressure (BP) and of fasting lipids obtained at baseline and every three months after initi- ation of the intervention",Morbidly obese patients were selected to participate in the study BMI greater than 40 kg/m2.,122.2,20.1,0.0,0.0,,45.8,5.0,36.0,55.599999999999994,,86.8,10.0,67.19999999999999,106.4,131.9,18.7,95.248,168.55200000000002,47.8,11.5,43.0,17.0,0.0,0.0,0.0,ILI,control,194696_Bartolomé Burguera_ILI,17.0;43.0,60.0,47.8(11.5),122.2(20.1),45.8(5.0),131.9(18.7),86.8(10.0)
23,194696,doi.org/10.1155/2015/194696,Bartolomé Burguera,2015,EUR,"Aimed at comparing the efficacy of two nonsurgical approaches versus bariatric surgery, on body weight changes and metabolic parameters in morbidly obese patients.",Randomised controlled trial,Spain,143.0,Both,Body weight in KGs and Body mass index in kg/m2.,"Percent changes in fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), and blood pressure (BP) and of fasting lipids obtained at baseline and every three months after initi- ation of the intervention",Morbidly obese patients were selected to participate in the study BMI greater than 40 kg/m2.,126.0,17.9,0.0,0.0,,46.8,4.6,37.784,55.815999999999995,,86.6,10.0,67.0,106.19999999999999,136.1,14.0,108.66,163.54,46.9,10.3,29.0,17.0,0.0,0.0,0.0,COT,control,194696_Bartolomé Burguera_COT,17.0;29.0,46.0,46.9(10.3),126.0(17.9),46.8(4.6),136.1(14.0),86.6(10.0)
24,194696,doi.org/10.1155/2015/194696,Bartolomé Burguera,2015,EUR,"Aimed at comparing the efficacy of two nonsurgical approaches versus bariatric surgery, on body weight changes and metabolic parameters in morbidly obese patients.",Randomised controlled trial,Spain,143.0,Both,Body weight in KGs and Body mass index in kg/m2.,"Percent changes in fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), and blood pressure (BP) and of fasting lipids obtained at baseline and every three months after initi- ation of the intervention",Morbidly obese patients were selected to participate in the study BMI greater than 40 kg/m2.,132.8,24.4,0.0,0.0,,49.2,5.9,37.636,60.764,,82.8,8.9,65.356,100.244,132.6,14.4,104.37599999999999,160.82399999999998,44.1,9.8,26.0,11.0,0.0,0.0,0.0,SOG,intervention,194696_Bartolomé Burguera_SOG,11.0;26.0,37.0,44.1(9.8),132.8(24.4),49.2(5.9),132.6(14.4),82.8(8.9)
25,32889869,10.1097/SLA.0000000000004339,Robert Caiazzo,2020,EUR,The aim of this study was to compare the efficacy and safety of 12-month implantation of a duodeno-jejunal bypass liner (DJBL) with conventional medical care in patients with metabolic syndrome (MS).,Randomised controlled trial,France,80.0,Both,primary aim was to evaluate the efficacy of DJBL in reducing MS prevalence at 1 year after implantation. Rate of resolution of MS.,"included body weight, glucose control (HbA1c and fasting blood glucose), blood pressure, lipids (plasma choles- terol, triglycerides). ","The participants had obesity, BMI greater than 30 kg/m2 and diagnosed with metabolic syndrome.",0.0,0.0,0.0,0.0,,38.4,0.0,36.8,39.9,,81.8,0.0,78.8,84.8,133.9,0.0,128.3,139.5,48.1,0.0,34.0,15.0,0.0,0.0,0.0,DJBL,intervention,32889869_Robert Caiazzo_DJBL,15.0;34.0,49.0,48.1(0.0),0.0(0.0),38.4(0.0),133.9(0.0),81.8(0.0)
26,32889869,10.1097/SLA.0000000000004339,Robert Caiazzo,2020,EUR,The aim of this study was to compare the efficacy and safety of 12-month implantation of a duodeno-jejunal bypass liner (DJBL) with conventional medical care in patients with metabolic syndrome (MS).,Randomised controlled trial,France,80.0,Both,primary aim was to evaluate the efficacy of DJBL in reducing MS prevalence at 1 year after implantation. Rate of resolution of MS.,"included body weight, glucose control (HbA1c and fasting blood glucose), blood pressure, lipids (plasma choles- terol, triglycerides). ","The participants had obesity, BMI greater than 30 kg/m2 and diagnosed with metabolic syndrome.",0.0,0.0,0.0,0.0,,37.9,0.0,36.3,39.5,,81.7,0.0,76.5,86.4,138.0,0.0,129.9,146.1,46.7,0.0,20.0,11.0,0.0,0.0,0.0,MT,control,32889869_Robert Caiazzo_MT,11.0;20.0,31.0,46.7(0.0),0.0(0.0),37.9(0.0),138.0(0.0),81.7(0.0)
27,28000425,10.1002/oby.21702,Shelby Sullivan,2016,EUR,To evaluate safety and efficacy of the poseTM procedure for obesity treatment.,Randomised controlled trials,USA,332.0,Both,Total body weight loss,"Comorbidities resolution, triglycerides","Patients with class I and II obesity, aged between 22 and 6o years",98.7,11.6,0.0,0.0,,36.2,2.2,31.888,40.512,,79.44,0.0,0.0,0.0,133.0,0.0,0.0,0.0,45.3,9.1,101.0,10.0,0.0,0.0,0.0,Sham,control,28000425_Shelby Sullivan_Sham,10.0;101.0,111.0,45.3(9.1),98.7(11.6),36.2(2.2),133.0(0.0),79.44(0.0)
28,28000425,10.1002/oby.21702,Shelby Sullivan,2016,EUR,To evaluate safety and efficacy of the poseTM procedure for obesity treatment.,Randomised controlled trials,USA,332.0,Both,Total body weight loss,"Comorbidities resolution, triglycerides","Patients with class I and II obesity, aged between 22 and 6o years",99.7,12.2,0.0,0.0,,36.0,2.4,31.296,40.704,,77.97,0.0,0.0,0.0,132.3,0.0,0.0,0.0,44.2,8.6,195.0,26.0,0.0,0.0,0.0,POSE,intervention,28000425_Shelby Sullivan_POSE,26.0;195.0,221.0,44.2(8.6),99.7(12.2),36.0(2.4),132.3(0.0),77.97(0.0)
29,31931977,10.1016/j.soard.2019.03.038,Donald C Simonson ,2019,Mixed,"This study examined resolution of hyperglycemia (A1C ,6.5% and fasting glucose ,126 mg/dL) 3 years after randomization to either a laparoscopic adjustable gastric band (LAGB) or 1-year diabetes and weight management (DWM) program.",Randomised controlled trials,USA,40.0,Both,"To attain normoglycemia, defined as fasting plasma glucose ,126 mg/dL and A1C ,6.5% at 1 year whether or not pharmacologic treatment was used",Patient reported outcomes e.g quality of life.,"The study participants had T2D for more than 1 year, aged between 21 and 65 years with a BMI between 30 and 45.",106.8,10.4,0.0,0.0,,36.4,3.0,30.52,42.28,,79.1,5.3,68.71199999999999,89.488,128.5,7.4,113.996,143.004,51.0,12.7,9.0,9.0,0.0,0.0,0.0,LAGB,intervention,31931977_Donald C Simonson _LAGB,9.0;9.0,18.0,51.0(12.7),106.8(10.4),36.4(3.0),128.5(7.4),79.1(5.3)
30,31931977,10.1016/j.soard.2019.03.038,Donald C Simonson ,2019,Mixed,"This study examined resolution of hyperglycemia (A1C ,6.5% and fasting glucose ,126 mg/dL) 3 years after randomization to either a laparoscopic adjustable gastric band (LAGB) or 1-year diabetes and weight management (DWM) program.",Randomised controlled trials,USA,40.0,Both,"To attain normoglycemia, defined as fasting plasma glucose ,126 mg/dL and A1C ,6.5% at 1 year whether or not pharmacologic treatment was used",Patient reported outcomes e.g quality of life.,"The study participants had T2D for more than 1 year, aged between 21 and 65 years with a BMI between 30 and 45.",111.6,17.9,0.0,0.0,,36.7,4.2,28.468000000000004,44.932,,80.9,8.1,65.024,96.77600000000001,126.2,13.0,100.72,151.68,51.6,7.5,9.0,13.0,0.0,0.0,0.0,DWM,control,31931977_Donald C Simonson _DWM,13.0;9.0,22.0,51.6(7.5),111.6(17.9),36.7(4.2),126.2(13.0),80.9(8.1)
31,30471927,10.1016/j.soard.2018.10.010,Boerboom Abel,2018,EUR,To evaluate the effect of a long biliopancreatic limb RYGB (LBP-GB) and standard RYGB (S-GB) as revisional procedure after laparoscopic adjustable gastric band,RCT,Netherlands,146.0,Both,%TBWL over a period of 4 years,"Reduction of obesity related co-morbidities (type 2 diabetes [T2D], hypertension [HT], and dyslipi- demia [DL]), perioperative complications, and quality of life (QoL)","These are participants who had previously undergone LAGB, however they were deemed failed since they did not achieve much weightless and thus recommended revisional RYGB. They have T2D,Hyperlipidemia and hypertension.",121.0,16.0,0.0,0.0,,42.0,4.0,34.16,49.84,,93.0,8.0,77.32,108.68,146.0,16.0,114.64,177.36,47.0,7.0,57.0,15.0,0.0,0.0,0.0,S-GB,control,30471927_Boerboom Abel_S-GB,15.0;57.0,72.0,47.0(7.0),121.0(16.0),42.0(4.0),146.0(16.0),93.0(8.0)
32,30471927,10.1016/j.soard.2018.10.010,Boerboom Abel,2018,EUR,To evaluate the effect of a long biliopancreatic limb RYGB (LBP-GB) and standard RYGB (S-GB) as revisional procedure after laparoscopic adjustable gastric band,RCT,Netherlands,146.0,Both,%TBWL over a period of 4 years,"Reduction of obesity related co-morbidities (type 2 diabetes [T2D], hypertension [HT], and dyslipi- demia [DL]), perioperative complications, and quality of life (QoL)","These are participants who had previously undergone LAGB, however they were deemed failed since they did not achieve much weightless and thus recommended revisional RYGB. They have T2D,Hyperlipidemia and hypertension.",123.0,20.0,0.0,0.0,,43.0,5.0,33.2,52.8,,95.0,11.0,73.44,116.56,151.0,19.0,113.75999999999999,188.24,47.0,9.0,61.0,11.0,0.0,0.0,0.0,LBP-GB,intervention,30471927_Boerboom Abel_LBP-GB,11.0;61.0,72.0,47.0(9.0),123.0(20.0),43.0(5.0),151.0(19.0),95.0(11.0)
33,23736733,10.1001/jama.2013.5835,Sayeed Ikramuddin,2013,Mixed,To compare Roux-en-Y gastric bypass with lifestyle and intensive medi cal management to achieve control of comorbid risk factors.,RCT,USA_Taiwan,120.0,Both,"An HbA1c of less than 7.0%, an LDL cholesterol level of less than 100 mg/dL (to convert to millimoles per liter, multiply by 0.0259), and systolic blood pressure less than 130 mm Hg, at the 12-month visit.","weight loss, adverse events, fasting glucose, HbA1c levels less than 6.0%, high-density lipoprotein (HDL) cholesterol and triglycerides levels, diastolic blood pressure, waist circum ference, and medications.",Participants had BMI between 30 and 39 and diagnosed with Diabetes at least for six months,98.8,14.0,0.0,0.0,,34.9,3.0,29.02,40.78,,78.0,12.0,54.480000000000004,101.52,127.0,15.0,97.6,156.4,49.0,9.0,38.0,22.0,0.0,0.0,0.0,RYGBplusLMM,intervention,23736733_Sayeed Ikramuddin_RYGBplusLMM,22.0;38.0,60.0,49.0(9.0),98.8(14.0),34.9(3.0),127.0(15.0),78.0(12.0)
34,23736733,10.1001/jama.2013.5835,Sayeed Ikramuddin,2013,Mixed,To compare Roux-en-Y gastric bypass with lifestyle and intensive medi cal management to achieve control of comorbid risk factors.,RCT,USA_Taiwan,120.0,Both,"An HbA1c of less than 7.0%, an LDL cholesterol level of less than 100 mg/dL (to convert to millimoles per liter, multiply by 0.0259), and systolic blood pressure less than 130 mm Hg, at the 12-month visit.","weight loss, adverse events, fasting glucose, HbA1c levels less than 6.0%, high-density lipoprotein (HDL) cholesterol and triglycerides levels, diastolic blood pressure, waist circum ference, and medications.",Participants had BMI between 30 and 39 and diagnosed with Diabetes at least for six months,97.9,17.0,0.0,0.0,,34.3,3.1,28.223999999999997,40.376,,79.0,10.0,59.4,98.6,132.0,14.0,104.56,159.44,49.0,8.0,34.0,26.0,0.0,0.0,0.0,LMM,control,23736733_Sayeed Ikramuddin_LMM,26.0;34.0,60.0,49.0(8.0),97.9(17.0),34.3(3.1),132.0(14.0),79.0(10.0)
35,1234567,https://doi.org/10.31925/farmacia.2019.1.13,Liviu Iosif,2019,EUR,To examine the impact of weight loss on oxidant-antioxidant profile in obese T2D patients,Randomised controlled trial,Romania,38.0,Male,Glycated haemoglobin levels HbA1c < 6%,Oxidative stress markers including adiponectin and leptin,"Obese male participants aged 30-65 years of age, BMI greater than 30 kg/m2 with T2D between 1 to 15 years.",0.0,0.0,0.0,0.0,,40.5,8.6,23.644000000000002,57.355999999999995,,90.0,10.0,70.4,109.6,135.0,12.0,111.48,158.52,0.0,0.0,0.0,17.0,0.0,0.0,0.0,DTG,control,1234567_Liviu Iosif_DTG,17.0;0.0,17.0,0.0(0.0),0.0(0.0),40.5(8.6),135.0(12.0),90.0(10.0)
36,1234567,https://doi.org/10.31925/farmacia.2019.1.13,Liviu Iosif,2019,EUR,To examine the impact of weight loss on oxidant-antioxidant profile in obese T2D patients,Randomised controlled trial,Romania,38.0,Male,Glycated haemoglobin levels HbA1c < 6%,Oxidative stress markers including adiponectin and leptin,"Obese male participants aged 30-65 years of age, BMI greater than 30 kg/m2 with T2D between 1 to 15 years.",0.0,0.0,0.0,0.0,,39.6,4.9,29.996000000000002,49.204,,80.0,10.0,60.4,99.6,130.0,13.75,103.05,156.95,0.0,0.0,0.0,19.0,0.0,0.0,0.0,LSG,intervention,1234567_Liviu Iosif_LSG,19.0;0.0,19.0,0.0(0.0),0.0(0.0),39.6(4.9),130.0(13.75),80.0(10.0)
37,23706413,10.1016/j.diabres.2013.04.005,Liang Ziwen,2013,East Asian,Comparing the efficacy of RYGB with usual medical care and Exenatide therapy in obese T2DM with hyperten,RCT,China,108.0,Both,"Change in cardiac function in patients undergoing RYGB surgery, usual care or GLP-1 therapy","secondary aims were to assess changes in metabolic parameters (BMI, HbA1c, HOMA-IR and lipids) and inflammation (hs-CRP, TNF-a, HMW-adiponectin) after a 12- month treatment period.","Obese people with T2DM and hypertension, BMI must be greater than 28 kg/m2 and lived with hypertension between 5 -10 years.",81.97,3.53,0.0,0.0,,30.48,0.94,28.6376,32.3224,,88.58,5.53,77.74119999999999,99.4188,160.81,7.77,145.5808,176.0392,50.81,5.44,9.0,22.0,0.0,0.0,0.0,RYGB,intervention,23706413_Liang Ziwen_RYGB,22.0;9.0,31.0,50.81(5.44),81.97(3.53),30.48(0.94),160.81(7.77),88.58(5.53)
38,23706413,10.1016/j.diabres.2013.04.005,Liang Ziwen,2013,East Asian,Comparing the efficacy of RYGB with usual medical care and Exenatide therapy in obese T2DM with hyperten,RCT,China,108.0,Both,"Change in cardiac function in patients undergoing RYGB surgery, usual care or GLP-1 therapy","secondary aims were to assess changes in metabolic parameters (BMI, HbA1c, HOMA-IR and lipids) and inflammation (hs-CRP, TNF-a, HMW-adiponectin) after a 12- month treatment period.","Obese people with T2DM and hypertension, BMI must be greater than 28 kg/m2 and lived with hypertension between 5 -10 years.",81.31,4.97,0.0,0.0,,30.94,1.96,27.0984,34.7816,,87.83,6.81,74.4824,101.1776,156.6,11.81,133.45239999999998,179.7476,51.75,6.7,12.0,24.0,0.0,0.0,0.0,usualcare,control,23706413_Liang Ziwen_usualcare,24.0;12.0,36.0,51.75(6.7),81.31(4.97),30.94(1.96),156.6(11.81),87.83(6.81)
39,23706413,10.1016/j.diabres.2013.04.005,Liang Ziwen,2013,East Asian,Comparing the efficacy of RYGB with usual medical care and Exenatide therapy in obese T2DM with hyperten,RCT,China,108.0,Both,"Change in cardiac function in patients undergoing RYGB surgery, usual care or GLP-1 therapy","secondary aims were to assess changes in metabolic parameters (BMI, HbA1c, HOMA-IR and lipids) and inflammation (hs-CRP, TNF-a, HMW-adiponectin) after a 12- month treatment period.","Obese people with T2DM and hypertension, BMI must be greater than 28 kg/m2 and lived with hypertension between 5 -10 years.",81.76,3.67,0.0,0.0,,30.28,1.44,27.4576,33.1024,,85.83,11.0,64.27,107.39,159.94,8.63,143.02519999999998,176.8548,50.94,5.89,10.0,24.0,0.0,0.0,0.0,usualcareplusexenatide,control,23706413_Liang Ziwen_usualcareplusexenatide,24.0;10.0,34.0,50.94(5.89),81.76(3.67),30.28(1.44),159.94(8.63),85.83(11.0)
40,24899464,10.1001/jamasurg.2014.514,Florencia Halperin,2014,Mixed, To test the feasibility of methods to conduct a larger multisite trial to determine the long-term effect of Roux-en-Y gastric bypass (RYGB) surgery compared with an intensive diabetes medical and weight management (Weight Achievement and Intensive Treatment [Why WAIT]) program for type 2 diabetes.,Randomised controlled trials,USA,43.0,Both,To attain glycemic control and HbA1c below 6.5%) at 1 year of follow-up.," Measures of cardiometabolic health, and patient-reported outcomes",Participants are persons aged between 21 and 65 years of age diagnosed with T2D more than 1 year before the study. BMI (30 to 42). All participants were receiving antihyperglycemic medications.,102.7,17.0,0.0,0.0,,36.5,3.4,29.836,43.164,,76.6,8.8,59.35199999999999,93.848,126.3,14.7,97.488,155.112,52.6,4.3,10.0,9.0,0.0,0.0,0.0,WhyWAIT,control,24899464_Florencia Halperin_WhyWAIT,9.0;10.0,19.0,52.6(4.3),102.7(17.0),36.5(3.4),126.3(14.7),76.6(8.8)
41,24899464,10.1001/jamasurg.2014.514,Florencia Halperin,2014,Mixed, To test the feasibility of methods to conduct a larger multisite trial to determine the long-term effect of Roux-en-Y gastric bypass (RYGB) surgery compared with an intensive diabetes medical and weight management (Weight Achievement and Intensive Treatment [Why WAIT]) program for type 2 diabetes.,Randomised controlled trials,USA,43.0,Both,To attain glycemic control and HbA1c below 6.5%) at 1 year of follow-up.," Measures of cardiometabolic health, and patient-reported outcomes",Participants are persons aged between 21 and 65 years of age diagnosed with T2D more than 1 year before the study. BMI (30 to 42). All participants were receiving antihyperglycemic medications.,104.6,15.5,0.0,0.0,,36.0,3.5,29.14,42.86,,81.7,7.4,67.196,96.20400000000001,132.8,10.5,112.22000000000001,153.38,50.7,7.6,13.0,6.0,0.0,0.0,0.0,RYGB,intervention,24899464_Florencia Halperin_RYGB,6.0;13.0,19.0,50.7(7.6),104.6(15.5),36.0(3.5),132.8(10.5),81.7(7.4)
42,12345678,https://doi.org/10.1016/j.ajme.2012.07.002,Hala Mourad Demerdash,2012,AFR,"Theaimofthisworkwastostudytheeffectof2commonlyperformedbariatricsurgical procedures; laparoscopicRoux-en-Ygastricbypass(RYGBP)andlaparoscopicgastricband (BAND), onthecardiovascularriskprofileinmorbidlyobesepatientsanditscorrelationwit the plasmaapolipoprotein(apo)A-IVlevel.",Randomised prospective study,Egypt,40.0,Both,"Datacollectedincludedchangesofbodymassindex(BMI),bloodpressure,fastingblood sugar, fastingseruminsulin,insulinresistance(HOMA-IR)andlipidprofile.Inaddition,apoA-IV was determinedbytheWesternblottechnique.",,No proper description of the participants,142.7,22.6,0.0,0.0,,46.2,2.56,41.1824,51.217600000000004,,91.5,10.2,71.50800000000001,111.49199999999999,148.6,18.0,113.32,183.88,39.0,4.5,14.0,2.0,0.0,0.0,0.0,RYGB,intervention,12345678_Hala Mourad Demerdash_RYGB,2.0;14.0,16.0,39.0(4.5),142.7(22.6),46.2(2.56),148.6(18.0),91.5(10.2)
43,12345678,https://doi.org/10.1016/j.ajme.2012.07.002,Hala Mourad Demerdash,2012,AFR,"Theaimofthisworkwastostudytheeffectof2commonlyperformedbariatricsurgical procedures; laparoscopicRoux-en-Ygastricbypass(RYGBP)andlaparoscopicgastricband (BAND), onthecardiovascularriskprofileinmorbidlyobesepatientsanditscorrelationwit the plasmaapolipoprotein(apo)A-IVlevel.",Randomised prospective study,Egypt,40.0,Both,"Datacollectedincludedchangesofbodymassindex(BMI),bloodpressure,fastingblood sugar, fastingseruminsulin,insulinresistance(HOMA-IR)andlipidprofile.Inaddition,apoA-IV was determinedbytheWesternblottechnique.",,No proper description of the participants,138.7,22.98,0.0,0.0,,45.8,2.7,40.507999999999996,51.092,,92.5,10.0,72.9,112.1,146.2,17.82,111.27279999999999,181.1272,37.0,6.0,15.0,3.0,0.0,0.0,0.0,BAND,control,12345678_Hala Mourad Demerdash_BAND,3.0;15.0,18.0,37.0(6.0),138.7(22.98),45.8(2.7),146.2(17.82),92.5(10.0)
